Key result
Isoxazole derivatives inhibit aldose reductase up to ~19-fold more potently than epalrestat.
Answers are grounded in this paper and cite their sources.
Isoxazole derivatives demonstrate potent in vitro and in silico inhibition of aldose reductase, suggesting potential as therapeutic agents for diabetic complications.
Diabetes mellitus (DM), which can result in a number of problems such as cataracts, neuropathy, retinopathy, nephropathy, and several cardiovascular illnesses, continues to be a growing issue despite major advancements in treatment approaches. Numerous scientists have targeted the polyol pathway as a target for intervention since it includes aldose reductase (ALR2, AR (E.C.1.1.1.21)), a crucial enzyme. Oxidative damage, NADPH depletion, and intracellular sorbitol buildup result from the overactivation of ALR2 brought on by hyperglycemia. Interest in creating novel ALR2 inhibitors (ALR2Is) with enhanced therapeutic characteristics has increased as a result of this circumstance. The amazing biological capabilities of isoxazole molecules led us to look into the biological properties of isoxazole and related compounds. We examined these isoxazoles' binding affinities and interactions in the ALR2 active site using thorough in vitro and in silico techniques. In comparison to the reference pharmaceutical epalrestat (EPR, K I 232.70 ± 15.51 nM), our results demonstrate that these isoxazoles efficiently inhibit ALR2 at nanomolar doses, with inhibition constants ( K I ) ranging from 12.13 ± 1.24 nM to 89.51 ± 4.68 nM. Important interactions between these isoxazoles and ALR2 are highlighted by the combined in vitro and in silico studies, indicating their potential as therapeutic agents against a range of pathological diseases. Furthermore, these substances that have ALR2 inhibitory properties could be useful as stand‐in treatments or preventative measures for diabetes problems.
No takes yet. Share an insight, caveat, or question.
Göner et al. (2025) studied Diabetes mellitus. Isoxazole derivatives vs. Epalrestat was evaluated on Aldose reductase (ALR2) inhibition. Isoxazole derivatives efficiently inhibited aldose reductase with inhibition constants ranging from 12.13 to 89.51 nM, compared to 232.70 nM for the reference drug epalrestat.
Synapse has enriched 10 related papers. Consider them for comparative context: